HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Aurobindo Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1190 as of 27 May 15:30.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Mar '25 is ₹ 8516 crore as compare to the Dec '24 revenue of ₹ 8137 crore. This represent the growth of 4.66% The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the decline of -100%.
  • The ebitda of Aurobindo Pharma Ltd for the Mar '25 is ₹ 1894 crore as compare to the Dec '24 ebitda of ₹ 1736 crore. This represent the growth of 9.08% The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -100%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 902.83 crore over 8 quarters. This represents a CAGR of 25.89% The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma announces board meeting date

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 26 May 20...

Read more

17 May 2025 16:08

News

Aurobindo Pharma Ltd Slips 3.92%, BSE Healthcare index Shed 1.06%

Aurobindo Pharma Ltd fell 3.92% today to trade at Rs 1194. The BSE Healthcare index is dow...

Read more

06 May 2025 09:30

News

Aurobindo Pharma drops after fire incident at Kakinada facility

The incident, which occurred on 27 April 2025, has prompted a temporary suspension of oper...

Read more

29 Apr 2025 16:22

News

CuraTeQ Biologics s.r.o. receives positive opinion for biosimilar Dazublys' from EMA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, announc...

Read more

26 Apr 2025 13:58

News

Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets

The drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD...

Read more

23 Apr 2025 12:05

News

Aurobindo Pharma rallies after receiving USFDA nod for Rivaroxaban tablets

The said drug is bioequivalent and therapeutically equivalent to the reference listed drug...

Read more

15 Apr 2025 10:07

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Suven Pharmaceuticals Ltd?

Market cap of Aurobindo Pharma Ltd is 69,782 Cr while Market cap of Suven Pharmaceuticals Ltd is 27,815 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd?

The stock performance of Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd?

As of May 27, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1190.95. On the other hand, Suven Pharmaceuticals Ltd stock price is INR ₹1092.65.

How do dividend payouts of Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Suven Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions